Key Takeaways
- • Global health tech M&A surged to 400 deals in 2025 (up 14% from 350 in 2024), with strategic rationale focused on AI-driven revenue growth and margin expansion—exemplified by the Smarter Technologies roll-up integrating Thoughtful and SmarterDx into Access Healthcare's RCM services platform.
- • Healthcare AI startups captured 55% of 527 total venture deals (~$14B) in 2025, up from 37% in 2024, with average round size climbing 42% to $29M—representing disproportionate capital concentration relative to healthcare's 18% share of U.S. GDP.
- • New health tech IPOs in 2024-2025 (Waystar, Tempus, Hinge Health, Omada, Caris Life Sciences, HeartFlow) generated $36.6B in market capitalization with 2x revenue growth and stronger free cash flow margins than comparable high-growth software companies, yet trade at a 10-20% discount due to market skepticism from prior generation failures.
- • AI-services-as-software business model innovation is delivering service-level outcomes with software-level margins (70%+), differentiating this cycle from historical bubbles; AI scribes achieved 3-year adoption curves versus 15 years for EHRs, driven by demonstrable ROI and implementation ease.
- • Bessemer Venture Partners concludes healthcare AI is not in a bubble, citing buyer-driven adoption (not vendor push), sustainable unit economics, and clinical outcome improvements as fundamental differentiators from the Dot Com Bubble era.
Summary
Bessemer Venture Partners' 2026 State of Health AI report presents evidence that healthcare AI has moved beyond speculative hype into a sustainable growth phase with structurally different characteristics than prior technology bubbles. The analysis rests on three core market signals: accelerating M&A activity, record venture deployment, and successful public market debuts of second-generation health tech companies.
M&A activity reached 400 deals globally in 2025, up from 350 in 2024. More significantly, the strategic rationale behind these transactions reflects genuine business logic rather than speculative fervor. Healthcare organizations and investors are pursuing AI acquisitions specifically for dual drivers: revenue acceleration and gross margin expansion. The Smarter Technologies acquisition—combining Thoughtful's AI growth engine with SmarterDx's clinical AI platform into Access Healthcare's revenue cycle management (RCM) services—exemplifies this pattern. Rather than standalone AI point solutions, buyers are pursuing integrated platforms that demonstrably improve operational efficiency and financial performance.
Venture capital deployment in health AI reached unprecedented levels. BVP identified 527 venture deals in 2025 totaling approximately $14 billion, nearly returning to pandemic-era funding levels. More tellingly, average round size climbed 42% to $29 million, and AI startups captured 55% of total healthcare venture deals, up from 37% in 2024. This concentration of capital in healthcare AI startups is mathematically disproportionate—for every $1 invested across all AI companies, $0.22 flows to healthcare AI startups, despite healthcare representing only 18% of U.S. GDP spending.
The public markets delivered validation through six health tech IPOs between 2024 and 2025 (Waystar, Tempus, Hinge Health, Omada, Caris Life Sciences, and HeartFlow) that collectively raised $36.6 billion in market capitalization after a two-year capital markets drought. These companies differ materially from the first generation of health tech IPOs that faltered in 2020-2021: they demonstrate 2x revenue growth rates and superior free cash flow margins relative to high-growth cloud software benchmarks. The Bessemer Health Tech Index showed new health tech stocks gained 18% in 2025, matching NASDAQ and S&P 500 performance while outpacing the Nasdaq Emerging Cloud Index (down 7%), yet these stocks still trade at a 10-20% valuation discount to comparable cloud software peers despite superior underlying metrics.
Bessemer's bubble-or-breakthrough analysis hinges on two structural innovations distinguishing this cycle. First, a new "AI-services-as-software" business model has emerged, delivering human-quality work outcomes with software-level gross margins exceeding 70%—a combination historically unavailable in either pure services or traditional software categories. Second, buyer adoption dynamics have inverted from vendor-driven to buyer-driven. AI scribes achieved mainstream adoption in three years versus 15 years for electronic health record (EHR) systems, driven by transparent return-on-investment metrics and low implementation friction. These factors, combined with demonstrable clinical outcome improvements, position healthcare AI on a fundamentally different trajectory than the Dot Com Bubble's hype-driven deployment cycle.
M&A activity reached 400 deals globally in 2025, up from 350 in 2024. More significantly, the strategic rationale behind these transactions reflects genuine business logic rather than speculative fervor. Healthcare organizations and investors are pursuing AI acquisitions specifically for dual drivers: revenue acceleration and gross margin expansion. The Smarter Technologies acquisition—combining Thoughtful's AI growth engine with SmarterDx's clinical AI platform into Access Healthcare's revenue cycle management (RCM) services—exemplifies this pattern. Rather than standalone AI point solutions, buyers are pursuing integrated platforms that demonstrably improve operational efficiency and financial performance.
Venture capital deployment in health AI reached unprecedented levels. BVP identified 527 venture deals in 2025 totaling approximately $14 billion, nearly returning to pandemic-era funding levels. More tellingly, average round size climbed 42% to $29 million, and AI startups captured 55% of total healthcare venture deals, up from 37% in 2024. This concentration of capital in healthcare AI startups is mathematically disproportionate—for every $1 invested across all AI companies, $0.22 flows to healthcare AI startups, despite healthcare representing only 18% of U.S. GDP spending.
The public markets delivered validation through six health tech IPOs between 2024 and 2025 (Waystar, Tempus, Hinge Health, Omada, Caris Life Sciences, and HeartFlow) that collectively raised $36.6 billion in market capitalization after a two-year capital markets drought. These companies differ materially from the first generation of health tech IPOs that faltered in 2020-2021: they demonstrate 2x revenue growth rates and superior free cash flow margins relative to high-growth cloud software benchmarks. The Bessemer Health Tech Index showed new health tech stocks gained 18% in 2025, matching NASDAQ and S&P 500 performance while outpacing the Nasdaq Emerging Cloud Index (down 7%), yet these stocks still trade at a 10-20% valuation discount to comparable cloud software peers despite superior underlying metrics.
Bessemer's bubble-or-breakthrough analysis hinges on two structural innovations distinguishing this cycle. First, a new "AI-services-as-software" business model has emerged, delivering human-quality work outcomes with software-level gross margins exceeding 70%—a combination historically unavailable in either pure services or traditional software categories. Second, buyer adoption dynamics have inverted from vendor-driven to buyer-driven. AI scribes achieved mainstream adoption in three years versus 15 years for electronic health record (EHR) systems, driven by transparent return-on-investment metrics and low implementation friction. These factors, combined with demonstrable clinical outcome improvements, position healthcare AI on a fundamentally different trajectory than the Dot Com Bubble's hype-driven deployment cycle.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.